Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 225

1.

Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms.

DiFilippo EC, Coltro G, Carr RM, Mangaonkar AA, Binder M, Khan SP, Rodriguez V, Gangat N, Wolanskyj A, Pruthi RK, Chen D, He R, Viswanatha DS, Lasho T, Finke C, Tefferi A, Pardanani A, Patnaik MM.

Leukemia. 2020 Feb 14. doi: 10.1038/s41375-020-0752-x. [Epub ahead of print] No abstract available.

PMID:
32060405
2.

Pregnancy outcomes in myeloproliferative neoplasms: A Mayo Clinic report on 102 pregnancies.

Gangat N, Joshi M, Shah S, Yogarajah M, Patnaik MM, Pardanani A, Wolanskyj-Spinner AP, Tefferi A.

Am J Hematol. 2020 Feb 5. doi: 10.1002/ajh.25748. [Epub ahead of print] No abstract available.

PMID:
32020655
3.

The extracellular sulfatase SULF2 promotes liver tumorigenesis by stimulating assembly of a promoter looping GLI1-STAT3 transcriptional complex.

Carr RM, Romecin Duran PA, Tolosa EJ, Ma C, Oseini AM, Moser CD, Banini BA, Huang J, Asumda F, Dhanasekaran R, Graham RP, Toruner MD, Safgren SL, Almada LL, Wang S, Patnaik MM, Roberts LR, Fernandez-Zapico ME.

J Biol Chem. 2020 Jan 27. pii: jbc.RA119.011146. doi: 10.1074/jbc.RA119.011146. [Epub ahead of print]

4.

Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system.

Alkharabsheh O, Patnaik MM, Gangat N, Begna KH, Alkhateeb HB, Shah MV, Hogan WJ, He R, Greipp P, Nguyen PL, Litzow MR, Al-Kali A.

Ann Hematol. 2020 Jan 23. doi: 10.1007/s00277-020-03917-7. [Epub ahead of print]

PMID:
31974678
5.

Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients.

Coltro G, Antelo G, Lasho TL, Finke CM, Pardanani A, Gangat N, Carr RM, Binder M, Mangaonkar AA, Ketterling R, Fernandez-Zapico ME, Robertson KD, Bosi A, Vannucchi AM, Tefferi A, Patnaik MM.

Am J Hematol. 2020 Jan 10. doi: 10.1002/ajh.25721. [Epub ahead of print] No abstract available.

PMID:
31925810
6.

Clinical utility of fluorescence in situ hybridization-based diagnosis of BCR-ABL1 like (Philadelphia chromosome like) B-acute lymphoblastic leukemia.

Anagnostou T, Knudson RA, Pearce KE, Meyer RG, Pitel BA, Peterson JF, Baughn LB, Reichard KK, Ketterling RP, Kloft-Nelson SM, Knutson DL, Khan SP, Gangat N, Litzow MR, Hogan WJ, Wolanskyj A, Al-Kali A, Begna KH, Elliott M, Pardanani A, Foran J, Shah M, Tefferi A, Alkhateeb H, Halling K, Rodriguez V, Greipp PT, Patnaik MM.

Am J Hematol. 2020 Mar;95(3):E68-E72. doi: 10.1002/ajh.25729. Epub 2020 Jan 26. No abstract available.

PMID:
31919873
7.

Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.

Coltro G, Mangaonkar AA, Lasho TL, Finke CM, Pophali P, Carr R, Gangat N, Binder M, Pardanani A, Fernandez-Zapico M, Robertson KD, Bosi A, Droin N, Vannucchi AM, Tefferi A, Hunter A, Padron E, Solary E, Patnaik MM.

Leukemia. 2019 Dec 13. doi: 10.1038/s41375-019-0690-7. [Epub ahead of print]

PMID:
31836856
8.

Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management.

Patnaik MM, Tefferi A.

Am J Hematol. 2020 Jan;95(1):97-115. doi: 10.1002/ajh.25684.

PMID:
31736132
9.

Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment.

Coltro G, Patnaik MM.

Curr Oncol Rep. 2019 Nov 14;21(11):101. doi: 10.1007/s11912-019-0855-6. Review.

PMID:
31728739
10.

Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms.

Tischer A, Antelo G, Coltro G, Finke CM, Gonsalves W, Pardanani A, Ketterling R, Mangaonkar A, Gangat N, Tefferi A, Patnaik MM, Lasho TL.

Leuk Res. 2019 Dec;87:106264. doi: 10.1016/j.leukres.2019.106264. Epub 2019 Oct 24. No abstract available.

PMID:
31706195
11.

Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of TET2 and ZRSR2 mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving CDK2NA/2NB and MTAP.

Li M, Shah M, Binder M, Lasho T, Carr R, Mangaonkar A, Gangat N, Coltro G, Tefferi A, Dao L, Peters M, Chiu A, Patnaik MM.

Am J Hematol. 2020 Feb;95(2):E31-E34. doi: 10.1002/ajh.25675. Epub 2019 Dec 4. No abstract available.

PMID:
31705546
12.

Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia.

Carr RM, Patnaik MM.

Curr Opin Hematol. 2020 Jan;27(1):2-10. doi: 10.1097/MOH.0000000000000553.

PMID:
31688455
13.

Bone marrow findings in Erdheim-Chester disease: increased prevalence of chronic myeloid neoplasms.

Goyal G, Ravindran A, Liu Y, He R, Shah MV, Bennani NN, Patnaik MM, Rech KL, Go RS; Mayo Clinic Histiocytosis Working Group.

Haematologica. 2020 Jan 31;105(2):e84-e86. doi: 10.3324/haematol.2019.234187. Print 2020. No abstract available.

14.

Correction to: Hybridization capture-based next-generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis.

He R, Devine DJ, Tu ZJ, Mai M, Chen D, Nguyen PL, Oliveira JL, Hoyer JD, Reichard KK, Ollila PL, Al-Kali A, Tefferi A, Begna KH, Patnaik MM, Alkhateeb H, Viswanatha DS.

Mod Pathol. 2019 Oct 7. doi: 10.1038/s41379-019-0378-6. [Epub ahead of print]

PMID:
31591496
15.

Advances in chronic myelomonocytic leukemia and future prospects: Lessons learned from precision genomics.

Mangaonkar AA, Patnaik MM.

Adv Cell Gene Ther. 2019 Apr;2(2). pii: e48. doi: 10.1002/acg2.48. Epub 2019 Jan 16.

PMID:
31559392
16.

Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients.

Mangaonkar AA, Swoboda DM, Coltro G, Lasho TL, Novotny PJ, Pophali P, Carr RM, Binder M, Finke CM, Gangat N, Al-Kali A, Begna KH, Reichard KK, Ketterling RP, Al Ali NH, Vafaii P, Zhang L, Padron E, Talati C, Patnaik MM.

Leukemia. 2020 Feb;34(2):656-661. doi: 10.1038/s41375-019-0574-x. Epub 2019 Sep 11. No abstract available.

PMID:
31511613
17.

Concomitant Erdheim-Chester disease and chronic myelomonocytic leukaemia: genomic insights into a common clonal origin.

Goyal G, Liu Y, Ravindran A, Al-Kali A, Go RS, Patnaik MM, Rech KL; Mayo Clinic Histiocytosis Working Group.

Br J Haematol. 2019 Oct;187(2):e51-e54. doi: 10.1111/bjh.16177. Epub 2019 Sep 2. No abstract available.

PMID:
31475353
18.

Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis.

He R, Devine DJ, Tu ZJ, Mai M, Chen D, Nguyen PL, Oliveira JL, Hoyer JD, Reichard KK, Ollila PL, Al-Kali A, Tefferi A, Begna KH, Patnaik MM, Alkhateeb H, Viswanatha DS.

Mod Pathol. 2019 Aug 30. doi: 10.1038/s41379-019-0359-9. [Epub ahead of print] Erratum in: Mod Pathol. 2019 Oct 7;:.

PMID:
31471587
19.

Iron deficiency anemia associated with extracorporeal photopheresis: A retrospective analysis.

Kuhn AK, Bartoo GT, Dierkhising RA, Mara KC, Winters JL, Patnaik MM, Gastineau DA, Adamski J, Merten JA.

J Clin Apher. 2019 Dec;34(6):666-671. doi: 10.1002/jca.21744. Epub 2019 Aug 22.

PMID:
31436854
20.

Practical limitations of monocyte subset repartitioning by multiparametric flow cytometry in chronic myelomonocytic leukemia.

Pophali PA, Timm MM, Mangaonkar AA, Shi M, Reichard K, Tefferi A, Pavelko K, Villasboas JC, Jevremovic D, Patnaik MM.

Blood Cancer J. 2019 Aug 16;9(9):65. doi: 10.1038/s41408-019-0231-7. No abstract available.

21.

QT prolongation in patients with acute leukemia or high-risk myelodysplastic syndrome prescribed antifungal prophylaxis during chemotherapy-induced neutropenia.

Barreto JN, Cullen MW, Mara KC, Grove ME, Sierzchulski AG, Dahl NJ, Tosh PK, Dierkhising RA, Patnaik MM, Ackerman MJ.

Leuk Lymphoma. 2019 Dec;60(14):3512-3520. doi: 10.1080/10428194.2019.1639165. Epub 2019 Jul 12.

PMID:
31298598
22.

Clinical Applications and Utility of a Precision Medicine Approach for Patients With Unexplained Cytopenias.

Mangaonkar AA, Ferrer A, Pinto E Vairo F, Cousin MA, Kuisle RJ, Gangat N, Hogan WJ, Litzow MR, McAllister TM, Klee EW, Lazaridis KN, Stewart AK, Patnaik MM.

Mayo Clin Proc. 2019 Sep;94(9):1753-1768. doi: 10.1016/j.mayocp.2019.04.007. Epub 2019 Jun 27.

PMID:
31256854
23.

Phenotypic heterogeneity associated with germline GATA2 haploinsufficiency: a comprehensive kindred study.

Haddox CL, Carr RM, Abraham RS, Perez Botero J, Rodriguez V, Pardanani A, Patnaik MM.

Leuk Lymphoma. 2019 Dec;60(13):3282-3286. doi: 10.1080/10428194.2019.1633630. Epub 2019 Jun 27. No abstract available.

PMID:
31246134
24.

Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.

Coltro G, Lasho TL, Finke CM, Gangat N, Pardanani A, Tefferi A, Jevremovic D, Altman JK, Patnaik MM.

Am J Hematol. 2019 Sep;94(9):E231-E234. doi: 10.1002/ajh.25552. Epub 2019 Jun 14. No abstract available.

PMID:
31173385
25.

Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial.

Gangat N, Marinaccio C, Swords R, Watts JM, Gurbuxani S, Rademaker A, Fought AJ, Frankfurt O, Altman JK, Wen QJ, Farnoud N, Famulare CA, Patel A, Tapia R, Vallapureddy RR, Barath S, Graf A, Handlogten A, Zblewski D, Patnaik MM, Al-Kali A, Dinh YT, Englund Prahl K, Patel S, Nobrega JC, Tejera D, Thomassen A, Gao J, Ji P, Rampal RK, Giles FJ, Tefferi A, Stein B, Crispino JD.

Clin Cancer Res. 2019 Aug 15;25(16):4898-4906. doi: 10.1158/1078-0432.CCR-19-1005. Epub 2019 May 6.

PMID:
31061068
26.
27.

Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions.

Valent P, Orazi A, Savona MR, Patnaik MM, Onida F, van de Loosdrecht AA, Haase D, Haferlach T, Elena C, Pleyer L, Kern W, Pemovska T, Vladimer GI, Schanz J, Keller A, Lübbert M, Lion T, Sotlar K, Reiter A, De Witte T, Pfeilstöcker M, Geissler K, Padron E, Deininger M, Orfao A, Horny HP, Greenberg PL, Arber DA, Malcovati L, Bennett JM.

Haematologica. 2019 Oct;104(10):1935-1949. doi: 10.3324/haematol.2019.222059. Epub 2019 May 2.

28.

Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease.

Goyal G, Ravindran A, Young JR, Shah MV, Bennani NN, Patnaik MM, Nowakowski GS, Thanarajasingam G, Habermann TM, Vassallo R, Sher T, Parikh SA, Rech KL, Go RS; Mayo Clinic Histiocytosis Working Group.

Haematologica. 2020 Jan 31;105(2):348-357. doi: 10.3324/haematol.2019.219626. Print 2020.

29.

Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients.

Coston T, Pophali P, Vallapureddy R, Lasho TL, Finke CM, Ketterling RP, Carr R, Binder M, Mangaonkar AA, Gangat N, Al-Kali A, Litzow M, Zblewski D, Pardanani A, Tefferi A, Patnaik MM.

Am J Hematol. 2019 Jul;94(7):767-779. doi: 10.1002/ajh.25488. Epub 2019 May 3.

PMID:
30964202
30.

Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia.

Lucas N, Duchmann M, Rameau P, Noël F, Michea P, Saada V, Kosmider O, Pierron G, Fernandez-Zapico ME, Howard MT, King RL, Niyongere S, Diop MK, Fenaux P, Itzykson R, Willekens C, Ribrag V, Fontenay M, Padron E, Soumelis V, Droin N, Patnaik MM, Solary E.

Leukemia. 2019 Oct;33(10):2466-2480. doi: 10.1038/s41375-019-0447-3. Epub 2019 Mar 20.

PMID:
30894665
31.

3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups.

Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, Finke C, Begna KH, Elliott MA, Hook CC, Wolanskyj AP, Patnaik MM, Hanson CA, Ketterling RP, Sirhan S, Pardanani A, Gangat N, Busque L, Tefferi A.

Mayo Clin Proc. 2019 Apr;94(4):599-610. doi: 10.1016/j.mayocp.2018.08.022. Epub 2019 Feb 26.

PMID:
30824279
32.

Utilization and Outcomes of Fertility Preservation Techniques in Women Undergoing Allogeneic Hematopoietic Cell Transplant.

Higgins A, Khan Z, Coddington CC, Hashmi SK, Hefazi M, Alkhateeb H, Litzow MR, Hogan WJ, Cathcart-Rake E, Thompson CA, Patnaik MM.

Biol Blood Marrow Transplant. 2019 Jun;25(6):1232-1239. doi: 10.1016/j.bbmt.2019.02.013. Epub 2019 Feb 15.

PMID:
30772513
33.

A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy.

Gangat N, Phelps A, Lasho TL, Finke CM, Vallapureddy R, Hanson CA, Ketterling RP, Patnaik MM, Pardanani A, Tefferi A.

Blood Cancer J. 2019 Jan 24;9(2):11. doi: 10.1038/s41408-018-0167-3. No abstract available.

34.

Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".

Patnaik MM, Tefferi A.

Am J Hematol. 2019 Apr;94(4):475-488. doi: 10.1002/ajh.25397. Epub 2019 Jan 24. Review.

PMID:
30618061
35.

Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation.

Patnaik MM, Pophali PA, Lasho TL, Finke CM, Horna P, Ketterling RP, Gangat N, Mangaonkar AA, Pardanani A, Tefferi A.

Haematologica. 2019 Jun;104(6):e236-e239. doi: 10.3324/haematol.2018.208082. Epub 2019 Jan 3. No abstract available.

36.

GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.

Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, Hansen MJ, Jin F, Ayasoufi K, Hefazi M, Schick KJ, Walters DK, Ahmed O, Chappell D, Sahmoud T, Durrant C, Nevala WK, Patnaik MM, Pease LR, Hedin KE, Kay NE, Johnson AJ, Kenderian SS.

Blood. 2019 Feb 14;133(7):697-709. doi: 10.1182/blood-2018-10-881722. Epub 2018 Nov 21.

37.

Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models.

Pardanani A, Shah S, Mannelli F, Elala YC, Guglielmelli P, Lasho TL, Patnaik MM, Gangat N, Ketterling RP, Reichard KK, Hanson CA, Vannucchi AM, Tefferi A.

Blood Adv. 2018 Nov 13;2(21):2964-2972. doi: 10.1182/bloodadvances.2018026245.

38.

Novel germline missense DDX41 variant in a patient with an adult-onset myeloid neoplasm with excess blasts without dysplasia.

Vairo FPE, Ferrer A, Cathcart-Rake E, King RL, Howard MT, Viswanatha DS, Klee EW, Mangaonkar AA, Patnaik MM.

Leuk Lymphoma. 2019 May;60(5):1337-1339. doi: 10.1080/10428194.2018.1522443. Epub 2018 Nov 8. No abstract available.

PMID:
30407884
39.

In Reply-Short Telomere Syndromes, Biological Aging, and Hematopoietic Stem Cell Transplantation.

Mangaonkar AA, Patnaik MM.

Mayo Clin Proc. 2018 Nov;93(11):1685-1687. doi: 10.1016/j.mayocp.2018.08.012. No abstract available.

PMID:
30392550
40.

Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients.

Miller KC, Al-Kali A, Shah MV, Hogan WJ, Elliott MA, Begna KH, Gangat N, Patnaik MM, Viswanatha DS, He R, Greipp PT, Sproat LZ, Foran JM, Litzow MR, Alkhateeb HB.

Leuk Lymphoma. 2019 Apr;60(4):990-999. doi: 10.1080/10428194.2018.1509318. Epub 2018 Oct 2.

PMID:
30277111
41.

45-Year-Old Man With Abdominal Pain and Splenomegaly.

Gast KC, Hoversten K, Patnaik MM.

Mayo Clin Proc. 2018 Nov;93(11):e113-e117. doi: 10.1016/j.mayocp.2018.02.028. Epub 2018 Sep 27. No abstract available.

PMID:
30269944
42.

Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide.

Tefferi A, Szuber N, Vallapureddy RR, Begna KH, Patnaik MM, Elliott MA, Christopher Hook C, Wolanskyj AP, Hanson CA, Ketterling RP, Pardanani A, Gangat N.

Am J Hematol. 2019 Jan;94(1):5-9. doi: 10.1002/ajh.25294. Epub 2018 Oct 17.

43.

A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status.

Begna KH, Ali W, Gangat N, Elliott MA, Al-Kali A, Litzow MR, Hook CC, Wolanskyj AP, Hogan WJ, Patnaik MM, Pardanani A, Zblewski DL, Chen D, He R, Viswanatha D, Hanson CA, Ketterling RP, Tefferi A.

Am J Hematol. 2018 Dec;93(12):E401-E404. doi: 10.1002/ajh.25290. Epub 2018 Oct 17. No abstract available.

44.

Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms.

Patnaik MM, Lasho T, Howard M, Finke C, Ketterling RL, Al-Kali A, Pardanani A, Droin N, Gangat N, Tefferi A, Solary E.

Blood Cancer J. 2018 Aug 22;8(9):82. doi: 10.1038/s41408-018-0120-5. No abstract available.

45.

Multiple isodicentric Y chromosomes in myeloid malignancies: a unique cytogenetic entity and potential therapeutic target.

Mangaonkar AA, Patnaik MM, Oliver GR, Rao KW, Kaiser-Rogers K, Davila JI, Fadra N, Wehrs RN, Elliott MA, Greipp PT, Halling KC, Van Dyke DL.

Leuk Lymphoma. 2019 Mar;60(3):821-824. doi: 10.1080/10428194.2018.1498492. Epub 2018 Aug 30. No abstract available.

PMID:
30160574
46.

Practice-relevant demarcation of systemic mastocytosis associated with another hematologic neoplasm.

Tefferi A, Shah S, Lasho TL, Patnaik MM, Reichard KK, Hanson CA, Ketterling RP, Pardanani A.

Am J Hematol. 2018 Dec;93(12):E383-E386. doi: 10.1002/ajh.25269. Epub 2018 Oct 17. No abstract available.

47.

Mutations and karyotype predict treatment response in myelodysplastic syndromes.

Idossa D, Lasho TL, Finke CM, Ketterling RP, Patnaik MM, Pardanani A, Gangat N, Tefferi A.

Am J Hematol. 2018 Nov;93(11):1420-1426. doi: 10.1002/ajh.25267. Epub 2018 Sep 30.

48.

Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases.

Shah S, Pardanani A, Elala YC, Lasho TL, Patnaik MM, Reichard KK, Hanson CA, Ketterling RP, Tefferi A.

Am J Hematol. 2018 Dec;93(12):1461-1466. doi: 10.1002/ajh.25265. Epub 2018 Sep 26.

49.

Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients.

Pophali P, Horna P, Lasho TL, Finke CM, Ketterling RP, Gangat N, Nagorney D, Tefferi A, Patnaik MM.

Am J Hematol. 2018 Nov;93(11):1347-1357. doi: 10.1002/ajh.25246. Epub 2018 Oct 5.

50.

Blast-phase chronic myelomonocytic leukemia: more than just semantics.

Patnaik MM, Tefferi A, Garcia-Manero G.

Leukemia. 2018 Sep;32(9):2093-2094. doi: 10.1038/s41375-018-0228-4. Epub 2018 Aug 7. No abstract available.

PMID:
30087420

Supplemental Content

Loading ...
Support Center